Key Takeaways Regeneron stock has dropped 21.1% YTD, underperforming the industry, sector, and S&P 500.Eylea sales face pressure from Roche's Vabysmo, while Eylea HD posts U.S. growth.Dupixent and new oncology approvals like Lynozyfic and Ordspono support Regeneron's outlook. Shares of Regeneron Pharmaceuticals ((REGN) have lost 21.1% year to date against the industry’s growth of 5.2%. The stock has also underperformed the sector and the S&P 500 Index during this time frame. While the stock has recovered so ...